Pittsburgh, Oct. 03, 2019 (GLOBE NEWSWIRE) -- Ariel Precision Medicine, Inc., a privately held integrated genomics and digital health company developing innovative solutions for complex chronic disease, announced that the Pittsburgh Technology Council has named Ariel Innovator of the Year in the Life Sciences category. Following their nomination, the council evaluated Ariel’s business accomplishments as well as their technology advancements, including the company’s flagship product, ADVANCE®, a cloud-based clinical decision support tool designed to simplify the diagnosis and treatment of pancreatic disease.
“When we founded Ariel, we knew we had a truly unique technology – one that had the potential to make a meaningful impact for the millions of people with pancreatitis, diabetes, pancreatic cancer and other chronic inflammatory conditions,” stated Jessica Gibson chief executive officer and co-founder of Ariel Precision Medicine. “Through the support of our stakeholders and the dedication of our employees, we’ve been able to bring this advanced technology to the market. It is extremely gratifying to be recognized for our labors by a community of our peers as a leader in life sciences technology innovation.”
The Pittsburgh Technology Council honors the top 50 innovative companies in the region in their annual Tech 50 awards based on their product and/or sales growth, corporate citizenship, job growth and retention, industry achievement and product or technology innovation. Innovator of the Year awards are bestowed in six categories: AI & Robotics, Community Tech, FinTech, Health IT, Life Sciences and Manufacturing.
About Ariel Precision Medicine
Ariel Precision Medicine is a private, Pittsburgh-based integrated genomics and digital health company creating solutions to enable early, personalized care of complex chronic diseases for patients anywhere. The company’s initial product, PancreasDx®, and its enterprise software platform, ADVANCE®, were developed with funds from a $2.5 million seed round. Learn more by visiting www.arielmedicine.com.
Disclaimer
This press release contains “forward-looking statements” concerning the development and commercialization of Ariel’s products, the potential benefits and attributes of such product or platform technology, and Ariel’s expectations regarding its prospects. Forward-looking statements are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements. These statements are made as of the date of this press release. Actual results may vary. Ariel undertakes no obligation to update any forward-looking statements for any reason.